This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Khan SA, Schuetz S, Hosseini O. Primary-site local therapy for patients with de novo metastatic breast cancer: an educational review. Ann Surg Oncol. 2022;29(9):5811–20.
Lane WO, Thomas SM, Blitzblau RC, et al. Surgical resection of the primary tumor in women with de novo stage IV breast cancer: contemporary practice patterns and survival analysis. Ann Surg. 2019;269(3):537–44.
Thomas A, Khan SA, Chrischilles EA, et al. Initial surgery and survival in stage IV breast cancer in the United States, 1988–2011. JAMA Surg. 2016;151(5):424–31.
Xiao W, Zou Y, Zheng S, et al. Primary tumor resection in stage IV breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2018;44(10):1504–12.
Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol. 2013;20(9):2828–34.
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380–8.
Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141–9.
Soran A, Ozmen V, Ozbas S, et al. Primary surgery with systemic therapy in patients with de novo stage IV breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial. J Am Coll Surg. 2021;233(6):742-751.e745.
Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE Trial. Ann Surg. 2019;269(6):1163–9.
Khan SA, Zhao F, Goldstein LJ, et al. Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108). J Clin Oncol. 2022;40(9):978–87.
Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738–46.
Anderson WF, Chen BE, Jatoi I, et al. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat. 2006;100(1):121–6.
Murata T, Jinno H, Takahashi M, et al. Clinicopathologic features of hormone-receptor-positive breast cancer patients with late recurrence. Breast J. 2019;25(1):9–15.
Khan SA, Zhao F, Goldstein L et al. Reply to B. Ulas Kahya et al. and A. Soran et al. J Clin Oncol 2022:JCO2200861.
Soran A, Aytac O, Ozbas S. Locoregional therapy for intact primary tumor in de novo stage IV breast cancer. J Clin Oncol. 2022:JCO2200802.
Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol. 1992;21(5):837–41.
Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearron MS, Peace KE. Intention to treat in clinical trials. In: KE Peace, editor. Statistical issues in drug research and development. New York, NY: Marcel Dekker; 1990. p. 331–50.
Abraha I, Montedori A. Modified intention to treat reporting in randomised controlled trials: systematic review. BMJ. 2010;340:c2697.
Sainani KL. Making sense of intention-to-treat. PM R. 2010;2(3):209–13.
Matilde Sanchez M, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Stat Med. 2006;25(7):1169–81.
D’Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues—the encounters of academic consultants in statistics. Stat Med. 2003;22(2):169–86.
Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.
Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials. 2011;12:106.
Eleftherios A. Makris and Atilla Soran have no disclosures to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Makris, E.A., Soran, A. Impact of Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer. Ann Surg Oncol 30, 1067–1071 (2023). https://doi.org/10.1245/s10434-022-12871-9